Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 63fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 34Vincristine 30Methotrexate 30Etoposide 29Cytarabine 28Dexamethasone 27Whole-Body Irradiation 25Doxorubicin 25Mycophenolic Acid 23Prednisone 22Tacrolimus 21Filgrastim 21Busulfan 19Antilymphocyte Serum 18venetoclax 17nelarabine 17Cyclosporine 17Calcium Dobesilate 17merphos 15Rituximab 14Radiotherapy 14Methylprednisolone 13Bortezomib 13pegaspargase 12dexamethasone acetate 11dexamethasone 21-phosphate 11Melphalan 11prednylidene 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡